ARID4A
Overview
ARID4A (AT-rich interaction domain 4A) encodes a subunit of the NuRD chromatin-remodeling complex involved in transcriptional regulation through chromatin modification. In cancer genomics, ARID4A is recurrently mutated alongside other chromatin-remodeling genes, contributing to epigenetic dysregulation in bladder and other cancers.
Alterations observed in the corpus
- Mutated in transitional cell carcinoma (TCC) of the bladder as part of the chromatin-remodeling gene alteration cluster (alongside ARID1A and other SWI/SNF and NuRD complex members); mutations in chromatin-remodeling genes collectively affect 58% of bladder TCC cases PMID:24121792.
- ARID4A is a SWI/SNF member altered in ~5% of 1,013 prostate cancers (prad_p1000), enriched in ETS-fusion-negative tumors alongside ARID1A, ARID2, and SMARCA1. PMID:29610475
Cancer types (linked)
- Bladder cancer (BLCA) — ARID4A co-mutated with ARID1A and other chromatin-remodeling genes in TCC; part of the dominant 58% chromatin-remodeling alteration burden in bladder cancer PMID:24121792.
Co-occurrence and mutual exclusivity
Therapeutic relevance
- No direct targeted therapy reported in the corpus. Chromatin-remodeling gene mutations collectively define a major alteration class in bladder TCC (58%) that may harbor epigenetic therapeutic vulnerabilities PMID:24121792.
Open questions
- Specific frequency of ARID4A mutations (as distinct from the ARID1A/ARID4A grouping) in TCC is not individually reported in the cited study; further resolution of within-class mutation frequencies is needed.
Sources
This page was processed by crosslinker on 2026-05-09. - PMID:29610475
This page was processed by wiki-cli on 2026-05-15.